They split up the sales force and changed up who manages who. What did you expect with major disruptions that don't make any business sense. The proof is in the decline of sales.
What is going on with Onglyza and Bydureon. This company has a drug in every category. Sales are not good and do not appear to be getting any better. Who made these decisions.
Company does have a drug in every category. Unfortunately you have Onglyza in the toilet. Heart failure in Savor trial and no managed care. Bydureon has been a flop since its inception. Harpoon anyone. What about Farxiga? It is quickly being caught by Jardiance and was never a threat to Invokana. Invokana is a better drug. No bladder cancer and more efficacious. Great times are ahead for these brands.
True, but things will improve once it's figured out what to do moving forward. IE, carrying oral sand injectables again in the same bag as a final effort to gain lost ground.
that's interesting. I guess it all depends on the bottom line and if sales have gone up or down since that decision was made
Volume has increased. That's the only thing saving the leaders ass because there is still "growth." Share has nosedived but volume is up, imagine if we maintained or grew out share AND the volume increased. Maybe they would pay for our internet then.
